Deterioration of bladder compliance after botulinum toxin A injection and discontinuation of medication for overactive bladder

被引:0
|
作者
Wada, Naoki [1 ]
Ishikawa, Mayumi [1 ]
Nagabuchi, Masaya [1 ]
Makino, Shogo [1 ]
Miyauchi, Kotona [1 ]
Abe, Noriyuki [1 ]
Kakizaki, Hidehiro [1 ]
机构
[1] Asahikawa Med Univ, Dept Renal & Urol Surg, 2-1-1-1 Midorigaoka Higashi, Asahikawa, Hokkaido 0788510, Japan
关键词
botulinum toxin type A; low compliance bladder; overactive bladder;
D O I
10.1002/iju5.12496
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: We report a case of deterioration of bladder compliance after botulinum toxin type A injection and discontinuation of medication for overactive bladder. Case presentation: A female patient with overactive bladder in her sixties had been visiting our outpatient clinic regularly for 4 years. She had received posterolateral spondylus fusion twice, which resulted in a compression fracture. She had been receiving a combination therapy of anticholinergics and beta 3-adrenoceptor agonist for the management of overactive bladder. She received botulinum toxin type A injection for refractory overactive bladder and discontinued medical treatment for overactive bladder. Three months after botulinum toxin type A injection, cystometry revealed the deterioration of bladder compliance. Renal dysfunction, hydronephrosis, and vesicoureteral reflux were shown. Renal function and hydronephrosis were improved after restarting anticholinergics and beta 3-adrenoceptor agonist therapy and inserting a temporary transurethral catheter. Conclusion: Deterioration of bladder compliance may occur after botulinum toxin type A injection and discontinuation of overactive bladder medication in some patients with underlying neurological disease.
引用
收藏
页码:384 / 388
页数:5
相关论文
共 50 条
  • [31] Botulinum toxin for overactive bladder: reaching a happy median
    Christopher P Smith
    Nature Clinical Practice Urology, 2006, 3 : 128 - 129
  • [32] The use of botulinum toxin in the treatment of refractory overactive bladder
    Mucksavage, Phillip
    Smith, Ariana L.
    Moy, M. Louis
    OSTOMY WOUND MANAGEMENT, 2006, 52 (12) : 28 - +
  • [33] The use of botulinum toxin a in idiopathic overactive bladder syndrome
    Gomez C.S.
    Kanagarajah P.
    Gousse A.
    Current Urology Reports, 2010, 11 (5) : 353 - 359
  • [34] BOTULINUM TOXIN DOSE ESCALATION IN PATIENTS WITH OVERACTIVE BLADDER
    Penaloza, Natalia Garcia
    Weinberger, James
    Nguyen, Anissa V.
    Gu, Cindy
    JOURNAL OF UROLOGY, 2024, 211 (05): : E1148 - E1148
  • [35] Botulinum toxin injections for adults with overactive bladder syndrome
    Duthie, James B.
    Vincent, Michael
    Herbison, G. Peter
    Wilson, David Iain
    Wilson, Don
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (12):
  • [36] Update on use of botulinum toxin to treat overactive bladder
    Smith C.P.
    Somogyi G.T.
    Current Bladder Dysfunction Reports, 2007, 2 (2) : 65 - 70
  • [37] Overactive Bladder Syndrome, Detrusor Overactivity and the Botulinum Toxin
    Truzzi, Jose Carlos
    REVIEWS ON RECENT CLINICAL TRIALS, 2015, 10 (02) : 128 - 134
  • [38] A botulinum toxin into the trigone in neurogenic overactive bladder non-responder to detrusor injection
    Citeri, M.
    Spinelli, M.
    Zanollo, L.
    Scroppo, F.
    Macrellino, E.
    Redaelli, T.
    EUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (03) : 213 - 213
  • [39] The clinical application of intravesical botulinum toxin A injection in patients with overactive bladder and interstitial cystitis
    Jiang, Yuan-Hong
    Jhang, Jia-Fong
    Kuo, Hann-Chorng
    TZU CHI MEDICAL JOURNAL, 2023, 35 (01): : 31 - 37
  • [40] Intravesical Injection of OnabotulinumtoxinA (Botulinum Toxin Type A) in Japanese Patients With Refractory Overactive Bladder
    Gotoh, Daisuke
    Torimoto, Kazumasa
    Takamatsu, Norimi
    Onishi, Kenta
    Morizawa, Yosuke
    Hori, Shunta
    Nakai, Yasushi
    Miyake, Makito
    Fujimoto, Kiyohide
    IN VIVO, 2024, 38 (03): : 1332 - 1337